Forde Kimberly A
Division of Gastroenterology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Curr Hepatol Rep. 2017 Jun;16(2):105-112. doi: 10.1007/s11901-017-0348-8. Epub 2017 May 22.
Chronic infection with hepatitis B affects more than 240 million persons worldwide and is a major public health concern. Despite national and global initiatives to promote hepatitis B elimination, including newborn vaccination, catch up vaccination in adolescents and high-risk adults, screening of the blood supply and treatment of those in need, both new infections and a reservoir of chronic infections continue to result in morbidity and mortality. As with many chronic diseases, racial and ethnic disparities are seen in hepatitis B virus infection.
The goal of this review is to synthesize the data concerning the burden of hepatitis B infection in African Americans and Hispanics, two racial/ethnic groups in the United States who encounter barriers in access to care, low engagement in care and low utilization of diagnostic and treatment services.
Recent data, though sparse in certain areas, continue to suggest differences in rates of incidence and prevalence of hepatitis B virus infection in African Americans, and differences in screening, specialty referral and initiation of therapy for African Americans and Hispanics. Data are lacking about differences in liver disease progression and manifestations in both African Americans and Hispanics.
Disparities in hepatitis B diagnosis, disease management, treatment and prevention remain for African Americans and Hispanics. These disparities require a commitment from governmental and public health organizations. The efforts should include increasing vaccination in those most susceptible to infection, screening those at highest risk for infection, initiating antiviral therapy in those who require it and monitoring for liver-related complications, such as decompensated cirrhosis and hepatocellular carcinoma in the chronically infected. This multi-pronged approach is necessary to realize hepatitis B elimination.
全球有超过2.4亿人感染慢性乙型肝炎,这是一个重大的公共卫生问题。尽管国家和全球都在采取举措促进消除乙型肝炎,包括新生儿接种疫苗、青少年和高危成年人补种疫苗、筛查血液供应以及治疗有需要的人群,但新感染病例和慢性感染源仍不断导致发病和死亡。与许多慢性疾病一样,乙型肝炎病毒感染存在种族和民族差异。
本综述的目的是综合有关非裔美国人和西班牙裔人群中乙型肝炎感染负担的数据,这两个种族/民族群体在美国面临着获得医疗服务的障碍、医疗参与度低以及诊断和治疗服务利用率低的问题。
近期数据虽然在某些领域较为稀少,但仍显示非裔美国人中乙型肝炎病毒感染的发病率和患病率存在差异,以及非裔美国人和西班牙裔在筛查、专科转诊和治疗启动方面存在差异。关于非裔美国人和西班牙裔人群中肝病进展和表现的差异的数据尚缺乏。
非裔美国人和西班牙裔在乙型肝炎诊断、疾病管理、治疗和预防方面仍存在差异。这些差异需要政府和公共卫生组织做出承诺。这些努力应包括提高最易感染人群的疫苗接种率、筛查感染风险最高的人群、对需要的人启动抗病毒治疗以及监测肝脏相关并发症,如慢性感染者中的失代偿性肝硬化和肝细胞癌。这种多管齐下的方法对于实现消除乙型肝炎是必要的。